

# Leading Market Driver In Minjuvi Or Monjuvi Industry 2025: Increase In Cancer Prevalence Driving Growth Of The Market

*The Business Research Company's  
Minjuvi Or Monjuvi Global Market Report  
2025 – Market Size, Trends, And Forecast  
2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, March 10, 2025

/EINPresswire.com/ -- How Has the  
Minjuvi or Monjuvi Market Performed,  
and What is Its Future Growth Potential?

•The Minjuvi or Monjuvi market has witnessed strong growth, expanding from \$XX million in 2024 to \$XX million in 2025, with a Compound Annual Growth Rate (CAGR) of XX%.



Updated 2025 Market  
Reports Released: Trends,  
Forecasts to 2034 – Early  
Purchase Your Competitive  
Edge Today!"

*The Business Research  
Company*

- Several key factors have driven this growth, including:
  - oIncreased approvals of combination therapies, improving treatment options.
  - oExpansion of patient access programs, enhancing drug availability.
  - oFavorable reimbursement policies for targeted therapies, reducing financial barriers.
  - oHigh mortality rates of untreated relapsed DLBCL, necessitating effective treatments.
  - oGrowing demand for biologics in oncology, shaping

treatment preferences.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20154&type=smp>

The Minjuvi or Monjuvi market is forecasted to reach \$XX million by 2029, with a CAGR of XX% during the projection period.

Factors expected to fuel this growth include:

- Increased focus on elderly cancer patients, who have higher treatment needs.
- Greater awareness of healthcare advancements, improving early diagnosis.
- Rising adoption of CD19-targeted therapies, expanding treatment options.
- Enhanced government and NGO funding for cancer research, fostering innovation.
- Higher cancer survivorship rates, leading to long-term treatment demand.

Notable trends shaping the market include:

- Monoclonal antibody advancements, refining cancer treatment.
- Orphan drug designations, incentivizing drug development.
- Transition from chemotherapy to immunotherapy, optimizing patient outcomes.
- Integration of artificial intelligence in drug discovery, accelerating innovation.
- Development of biosimilars, increasing treatment accessibility.

What Drives Growth in the Minjuvi or Monjuvi Market?

The rising incidence of cancer worldwide is a major driver for the Minjuvi or Monjuvi market.

Cancer, characterized by uncontrolled cell growth, is influenced by factors such as:

- Aging populations, increasing cancer susceptibility.
- Unhealthy lifestyle habits, including smoking and poor diet.
- Environmental exposures, contributing to genetic mutations.
- Genetic predispositions, heightening risk factors.
- Improved diagnostic technologies, enhancing early detection.

Minjuvi (Monjuvi), combined with lenalidomide, has emerged as a breakthrough therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It effectively targets cancer cells, providing better treatment outcomes.

For example, a 2024 report from the Australian Institute of Health and Welfare projected that cancer diagnoses in Australia will rise from 169,000 in 2024 to 209,000 by 2034. Furthermore, cancer is expected to cause 3 out of every 10 deaths in the country, underscoring the need for advanced therapies like Minjuvi or Monjuvi.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/minjuvi-or-monjuvi-global-market-report>

Who are the Leading Companies in the Minjuvi or Monjuvi Market?

One of the major players in the Minjuvi or Monjuvi market is Incyte Corporation. This biopharmaceutical company focuses on researching, developing, and commercializing innovative medicines to address critical unmet medical needs in oncology and other serious conditions.

What Key Trends Are Reshaping the Minjuvi or Monjuvi Market?

- A significant trend in the market is the adoption of combination therapies, which improve treatment effectiveness and patient outcomes for B-cell malignancies like relapsed or refractory DLBCL.

- Combination therapy involves using multiple treatments simultaneously, targeting different disease pathways for optimal results.

For instance, in February 2024, Knight Therapeutics Inc., a Canadian pharmaceutical company, launched Minjuvi (tafasitamab) in Brazil through its partner United Medical Ltda.

- Minjuvi (tafasitamab) + lenalidomide is an immunotherapy for relapsed or refractory DLBCL patients who cannot undergo autologous stem cell transplantation.

- This combination achieved a high objective response rate, and the National Comprehensive Cancer Network (NCCN) guidelines now recommend it as a preferred second-line treatment.

### How is the Minjuvi or Monjuvi Market Structured?

The Minjuvi or Monjuvi market is categorized based on indication, formulation, distribution channel, and patient demographics:

- By Indication:

- oRelapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

- oOther B-Cell Malignancies

- By Formulation:

- oIntravenous Infusion

- oPre-Filled Syringes

- By Distribution Channel:

- oHospitals

- oOncology Clinics

- oSpecialty Pharmacies

- oHome Healthcare Services

- By Patient Demographics:

- oAdult Patients

- oGeriatric Patients

### Regional Analysis of the Minjuvi or Monjuvi Market

- North America was the leading market for Minjuvi or Monjuvi in 2024, due to:

- oAdvanced healthcare infrastructure, facilitating drug availability.

- oStrong biotechnology sector, driving oncology research.

- oFavorable reimbursement policies, improving patient access.

- Asia-Pacific is expected to be the fastest-growing region, supported by:

- oIncreasing healthcare investments, improving treatment accessibility.

- oRising cancer prevalence, driving demand for novel therapies.

- oExpanding government initiatives in oncology research, fostering drug development.

The Minjuvi or Monjuvi market report also provides insights into Western Europe, Eastern Europe, South America, the Middle East, and Africa, offering a comprehensive regional perspective.

Browse For More Similar Reports-

Anthracycline Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report>

Antibody Drug Conjugates Contract Manufacturing Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-contract-manufacturing-global-market-report>

Blood Cancer Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report>

Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [info@tbrc.info](mailto:info@tbrc.info)

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: [https://twitter.com/tbrc\\_info](https://twitter.com/tbrc_info)

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/792387149>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.